ABSTRACT
There is a rising rate of pulmonary disorders with high rates of death and morbidity. In this line, pulmonary drug delivery is emerging as a smart, noninvasive move for the treatment of an assortment of pathogenic disarrays. New classes of pharmaceuticals and biologic agents (DNA, proteins, peptides, etc.) are fueling the rapid evolution of drug delivery technologies for pulmonary disorders. Typically, these new therapeutic candidates cannot be delivered effectively by conventional methods (Figure 11.1). Furthermore, for many conventional pharmaceutical therapies, it has been determined that the efcacy may be improved and side effects reduced if the therapy is administered via a sustained and controlled fashion rather than through conventional burst release techniques (oral, intravenous, intraperitoneal, etc.).
